Thyrocare Technologies Limited
Thyrocare Technologies Limited Fundamental Analysis
Thyrocare Technologies Limited (THYROCARE.NS) shows moderate financial fundamentals with a PE ratio of 42.37, profit margin of 17.38%, and ROE of 26.02%. The company generates $2.6B in annual revenue with strong year-over-year growth of 20.19%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 93.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze THYROCARE.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentTHYROCARE.NS demonstrates superior asset utilization.
Valuation Score
ModerateTHYROCARE.NS shows balanced valuation metrics.
Growth Score
ExcellentTHYROCARE.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentTHYROCARE.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentTHYROCARE.NS achieves industry-leading margins.
Key Financial Metrics
Is THYROCARE.NS Expensive or Cheap?
P/E Ratio
THYROCARE.NS trades at 42.37 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, THYROCARE.NS's PEG of -5.82 indicates potential undervaluation.
Price to Book
The market values Thyrocare Technologies Limited at 10.92 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 7.76 times EBITDA. This is generally considered low.
How Well Does THYROCARE.NS Make Money?
Net Profit Margin
For every $100 in sales, Thyrocare Technologies Limited keeps $17.38 as profit after all expenses.
Operating Margin
Core operations generate 23.52 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $26.02 in profit for every $100 of shareholder equity.
ROA
Thyrocare Technologies Limited generates $20.24 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Thyrocare Technologies Limited produces operating cash flow of $423.11M, showing steady but balanced cash generation.
Free Cash Flow
Thyrocare Technologies Limited generates strong free cash flow of $370.56M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.98 in free cash annually.
FCF Yield
THYROCARE.NS converts 5.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
42.37
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-5.82
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.92
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.45
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.65
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.26
vs 25 benchmark
ROA
Return on assets percentage
0.20
vs 25 benchmark
ROCE
Return on capital employed
0.33
vs 25 benchmark
How THYROCARE.NS Stacks Against Its Sector Peers
| Metric | THYROCARE.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 42.37 | 28.45 | Worse (Expensive) |
| ROE | 26.02% | 763.00% | Weak |
| Net Margin | 17.38% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.65 | 2795.60 | Strong Liquidity |
| ROA | 20.24% | -16588.00% (disorted) | Strong |
THYROCARE.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Thyrocare Technologies Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
56.85%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
2.33%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
12.83%
Industry Style: Defensive, Growth, Innovation
High Growth